MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, APGE had -$16,572K decrease in cash & cash equivalents over the period. -$54,255K in free cash flow.

Cash Flow Overview

Change in Cash
-$16,572K
Free Cash flow
-$54,255K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-65,021 -121,435
Depreciation expense
406 606
Equity-based compensation expense
11,877 22,470
Amortization of discounts on marketable securities
1,620 4,139
Non-cash lease expense
940 1,778
Prepaid expenses and other current assets
2,106 1,642
Other non-current assets
181 8,359
Accounts payable
-5,302 4,607
Operating lease liability
-992 -1,985
Accrued expenses
7,744 -2,407
Net cash used in operating activities
-54,255 -110,506
Purchases of marketable securities
107,632 145,580
Maturities of marketable securities
125,577 241,772
Purchases of property and equipment
0 5,085
Net cash provided by (used in) investing activities
17,945 91,107
Proceeds from issuance of common stock, net of issuance costs
0 0
Proceeds from issuance of common stock under the atm, net of issuance costs
19,382 -
Proceeds from exercise of options and employee stock purchase plan purchases
356 1,802
Net cash provided by financing activities
19,738 1,802
(decrease) increase in cash, cash equivalents and restricted cash
-16,572 -17,597
Cash and cash equivalents at beginning of period
142,083 -
Cash and cash equivalents at end of period
107,914 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics, Inc. (APGE)